Adverse effects: euphoric behaviour · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: euphoric behaviour compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · topical urea 10%
SoF9. Change in taste short-term (Quantitative Sensory Testing gustative threshold): single study narratively reported no difference in short-term gustation thresholds; 38 participants (1 RCT, topical urea); very low.
1 study · 38 participants
Very low
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in quality of life (QoL) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in QoL - anxiety (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in QoL - anxiety (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in taste compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- vitamins) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · gabapentin with adjunctive ALA
SoF2 subgroup. Gabapentin + adjunctive ALA vs placebo forms one of two subgroups of the anticonvulsant symptom-relief estimate (RR 4.00, 2.09 to 7.67); no between-subgroup difference vs gabapentin alone; 100…
1 study · 40 participants
Very low
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF1. Change in QoL short-term (mean Beck Depression Inventory, 0-63, lower better): this single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but…
1 study · 37 participants
Very low
Adverse events: worsening of hypertension · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (alpha lipoic acid +/- adjunctive ingredients) changes adverse effects: increase in blood pressure compared with placebo (very low certainty).
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in pain reduction (VAS 0-10) compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase showed no clear difference in physician Global Assessment (Thongprasom score) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Partial response (remarkably effective or effective) · People with erosive oral lichen planus
Radix tripterygium hypoglaucum tablet (THT) led to lower partial response (remarkably effective or effective) compared with tripterygium glucosides tablet (TGT); GRADE not reported.
2 findings from 1 review